Editorial: serum triiodothyronine-to-thyroxine (T3/T4) ratio as biomarker of response in IBD - an open issue

Lorenzo Bertani^{1

2}, Domenico Tricò^{3

4}

Affiliations

¹ Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
² Department of General Surgery, Tuscany North-West ASL, Pontedera Hospital, Pontedera, Italy.
³ Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
⁴ Sant'Anna School of Advanced Studies, Institute of Life Sciences, Pisa, Italy.

Editorial

Lorenzo Bertani et al. Aliment Pharmacol Ther. 2022 Sep.

. 2022 Sep;56(5):903-904.

doi: 10.1111/apt.17136.

Lorenzo Bertani^{1

2}, Domenico Tricò^{3

4}

¹ Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
² Department of General Surgery, Tuscany North-West ASL, Pontedera Hospital, Pontedera, Italy.
³ Department of Surgical, Medical and Molecular Pathology and Critical Care Medicine, University of Pisa, Pisa, Italy.
⁴ Sant'Anna School of Advanced Studies, Institute of Life Sciences, Pisa, Italy.

No abstract available

Comment on

Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease?
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, Goodhand JR; PANTS consortium. Lin S, et al. Aliment Pharmacol Ther. 2022 Sep;56(5):783-793. doi: 10.1111/apt.17089. Epub 2022 Jun 29. Aliment Pharmacol Ther. 2022. PMID: 35768996 Free PMC article.

1. Hindryckx P, Vande Casteele N, Novak G, Khanna R, D’Haens G, Sandborn WJ, et al. The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug[s] for our patients? J Crohns Colitis. 2018;12(1):105-19.
1. Xu G, Yan W, Li J. An update for the controversies and hypotheses of regulating nonthyroidal illness syndrome in chronic kidney diseases. Clin Exp Nephrol. 2014;18(6):837-43.
1. Shizuma T. Concomitant thyroid disorders and inflammatory bowel disease: a literature review. Biomed Res Int. 2016;2016:5187061.
1. Bertani L, Trico D, Pugliese D, Privitera G, Linsalata G, Zanzi F, et al. Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients. Aliment Pharmacol Ther. 2021;53:273-280.
1. Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, et al. Understanding anti-TNF treatment failure: does serum triiodothyronine-to-thyroxine (T3/T4) ratio predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn's disease? Aliment Pharmacol Ther. 2022;56:783-793.